OL-108
/ Overland Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 20, 2025
A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
(clinicaltrials.gov)
- P1 | N=44 | Recruiting | Sponsor: Beijing GoBroad Hospital
New P1 trial • ANCA Vasculitis • Immunology • Inflammatory Arthritis • Lupus • Myositis • Scleroderma • Systemic Lupus Erythematosus • Systemic Sclerosis • Vasculitis
1 to 1
Of
1
Go to page
1